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The drug commonly known as U-47700 is a strong µ-opioid agonist with an approximate
potency 7.5 times higher than morphine. It has been available in Europe since 2014,
where it is usually sold through the internet or black market as an abuse morphine-like
substance. In the case reported here, a Caucasian man was found dead in his apartment.
Next to the body, the police seized one transparent plastic bag containing a white powder
and two amber glass bottles with nasal spray containing few milliliters of a transparent
liquid. During the autopsy, no evidence of natural disease or traumawas found to account
for the death. Blood, urine and pubic hair were collected and submitted for toxicological
analysis. The content of the seized materials was also submitted to a general screening
analysis in order to determine its composition. U-47700 was detected in blood, urine
and hair samples using an UHPLC/MS-MS method purposely developed. The blood
and urine concentrations were 380 and 10,400 ng/mL, respectively. No other drugs
of abuse nor ethanol were found in blood and urine specimens. Pubic hair analysis
revealed a frequent past exposure to U-47700. Finally, U-47700 was identified as the
main component of the powder and the liquids contained in the nasal spray bottles.
The combined circumstantial elements and toxicological results of the case revealed the
occurrence of an acute intoxication produced by U-47700 abuse. To the best of our
knowledge, this is the first fatal intoxication case reported on the Italian territory involving
the synthetic opioid U-47700.
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INTRODUCTION
U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide) is an
opioid analgesic drug developed by the pharmaceutical company Upjohn in the 1970s and
structurally related the earlier opioid AH-7921 (Belgian Early Warning System Drug, 2017). At
the moment, it is controlled in 3 European countries (Sweden, Finland and United Kingdom) and
in the USA. U-47700 is a strong µ-opioid receptor agonist, and reproduces all (or most of the)
common effects of opiates such as morphine, including analgesia, pronounced euphoria, sedation
and itching (Nikolaou et al., 2017). For these reasons, the compound is gaining popularity on drug
user forums as a legal alternative to morphine/heroin (Zawilska, 2017). It is generally sold online
as research chemical, not for human consumption, as a white or slightly pinkish powder or fine
crystals under different names, including “U4”, “Pink,” or “Pinky.” There is limited information
available on the routes of administration and the doses of U-47700 used. It is taken by oral, nasal,
Gerace et al. Fatal Intoxication by U-47700
rectal routes, or by smoking, intravenous injection, or even
by combinations of these routes (Nikolaou et al., 2017;
Zawilska, 2017). Side effects, including overdose reactions, are
presumed to be very similar to other opiates/opioids as well:
depressed respiration (slow breathing), miosis (pinpoint pupils),
constipation (World Health Organization, 2016; Baumann and
Pasternak, 2018). Even if several cases of acute and lethal
intoxication involving U-47700 were reported and reviewed in
the literature (Rambaran et al., 2017; Gerace et al., 2018), little is
still known about the correlation between its blood concentration
and the observed effects. In this investigation, we report a case
of fatal intoxication after U-47700 intake. The presence of the
drug was confirmed in blood, urine and pubic hair specimens by
means of mass spectrometry-based chromatographic methods.
BACKGROUND
Case History
A Caucasian man, with previous history of drug addiction, was
found dead in his apartment, lay down on the floor. Two amber
glass bottles with nasal spray, containing few mL of a transparent
liquid, plus a plastic bag containing a white powder were found
on a table near the decedent. Moreover, a package containing
a vial of naloxone hydrochloride 0.4 mg/mL was also found on
the table. No evidence of violence was observed in the room.
The death was reported to the Public Prosecutor who took
jurisdiction of the case. To investigate the cause of death, he
ordered a post-mortem examination and toxicological analysis.
Post-mortem Examination
The findings were irrelevant, except for a general pulmonary
edema. The body appeared well-nourished, and the internal
examination presented no evidence of natural disease or trauma
to account for his death. At the external examination of
the body, no signs of injection was found. To execute the
inherent toxicological analyses, heart blood, urine and pubic
hair (length: 3 cm) specimens were collected during the post-
mortem examination. Peripheral blood was not collected. All of
the samples were stored at−20◦C before the analysis.
EXPERIMENTAL
Samples Preparation for Fluids and Pubic
Hair
General screening analysis was executed according to a standard
procedure employed in our laboratory (Gerace et al., 2014).
Briefly, urine sample was extracted with tert-butyl methyl ether
(TBME) at alkaline condition after a deconjugation with β-
glucuronidase from E. coli. After mixing and centrifugation, the
organic layer was separated and dried under a nitrogen flow.
The residue was reconstituted with 50 µL of methanol and a
1 µL aliquot was injected into the gas chromatography/mass
spectrometry (GC/MS) system. In addition, the blood sample
was screened with a method for the detection of about ninety
pharmaceutical drugs and metabolites routinely employed in our
laboratory (Vincenti et al., 2013). For U-47700 quantitation in
blood, 50 µL of samples were added with the internal standard
(fentanyl-d5) at final concentration of 50 ng/mL and added
with 950 µL of acetonitrile/methanol 80:20 (v/v), previously
stored at −20◦C, and then incubated at −20◦C for 15min.
For quantitation in urine 50 µL of samples were added with
the internal standard (fentanyl-d5) at final concentration of
50 ng/mL and added with 950 µL of water with formic acid
5 mM/acetonitrile 95:5 (v/v). In both cases, the sample was
centrifuged at 14,000 rpm for 5min and 100 µL of the organic
phase was transferred into a new vial. Finally, 1 µL aliquot was
directly injected into the UHPLC-MS/MS system operating in
selected reaction monitoring (SRM) mode.
Pubic hair analysis was performed on the entire length of
the hair lock (3 cm). Approximately 50mg of hair was twice-
washed with dichloromethane and methanol (3mL each, vortex
mixed for 3min). After complete removal of the solvent wash,
the hair was dried at room temperature by a gentle nitrogen
flow and subsequently pulverized with a ball mill. For U-47700
quantitation, the hair sample was fortified with 3 µL of a
fentanyl-d5 dilute solution used as the internal standard at a
final concentration of 0.3 ng/mg. After the addition of 1mL of
methanol, the sample was incubated at 55◦C for 15 h without
stirring. Finally, the vial was centrifuged once more at 14,000
rpm for 5min and 1 µL aliquot was directly injected into the
UHPLC-MS/MS system operating in SRMmode.
The linear calibration model was checked by analyzing
blank hair samples spiked with standard solutions at final
concentration of 0, 0.01, 0.025, 0.05, 0.1, and 0.25 ng/mg.
Whenever the effective drug concentration exceeded the
calibration range, the samples were diluted to fit the quantitation
interval considered in the curve.
Moreover, qualitative and quantitative hair analyses for the
detection of (i) the most common drugs of abuse, (ii) synthetic
cannabinoids and (iii) synthetic cathinones were performed by
means of analytical methods used in our laboratory and described
elsewhere (Di Corcia et al., 2012; Salomone et al., 2014, 2016).
Sample Preparation for Liquids and
Powder Found on the Scene
The liquids and the powder found on the scene were subjected
to systematic analysis for the detection of drugs and toxic
substances. A 100 µL aliquot of liquid and 100mg of the powder
were dissolved in 5mL of methanol. After sonication in an
ultrasound bath for 1 h at 55◦C, a 1 µL aliquot of methanolic
solution was injected into the GC/MS system with the mass
spectrometer acquiring the spectra in the full scan mode (40–650
amu).
Apparatus and Methods
Preliminary screening analyses for amphetamines, tricyclic
antidepressants, barbiturates, benzodiazepines, cannabinoids,
methadone, cocaine and opiates were performed on urine by
the Enzyme Multiplied Immunoassay Technique (EMIT, Abbott
Laboratories, IL, USA). The presence of ethanol in the blood
was determined by headspace-GC-MS. Screening analysis for
unknown substances was performed using a 6890NGC apparatus
(Agilent Technologies, Milan, Italy) equipped with a HP−5
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17m fused-silica capillary column (J&W Scientific) with a 0.2-
mm inner diameter and a 0.33–µm film thickness. Full scan
spectra in the interval 40–650 amu were acquired using a 5,975
inert mass-selective detector (Agilent Technologies, Milan, Italy)
operating in the EI mode at 70 eV. The qualitative identification
of the underivatized compounds was performed by comparing
the full scan spectra obtained with those recorded in the
updated spectra libraries (PMWTox2, SWGDRUG version 3.0,
AAFS2012, CaymanSpectraLib). For the U-47700 confirmation
analysis, a dedicated UHPLC-MS/MS procedure was developed
as follows. The chromatographic separation was performed
using a Shimadzu LC-30A series system (Shimadzu, Duisburg,
Germany) equipped with a CORTECS UPLC C18 column
1.6µm × 2.1mm × 100mm (Waters Corporation, Italy).
The elution solvents were water/formic acid 5mM (solvent A)
and acetonitrile/formic acid 5mM (solvent B). After an initial
isocratic condition at 95% A for 0.5min, the mobile phase
composition was varied by a linear gradient (A:B; v/v) from
95:5 to 45:55 in 4.0min; followed by isocratic elution at 55%
B for 0.5min. The flow rate was 0.5 mL/min and the total
run time was 6.0min including re-equilibration at the initial
conditions before each injection. Detection was carried out by an
API 5500 triple quadrupole mass spectrometer (ABSCIEX, Foster
City, CA, USA) equipped with turbo ion spray source, operating
in the positive ionization mode. The SRM transitions used for
the determination of U-47700 were 330.9→286.1 (quantifier)
and 330.9→204.1 (qualifier), while for the internal standard the
transitions 342.2→188.2 was chosen.
Validation of the LC-MS Confirmation
Methods for U-47700 Quantitation
The method was validated by investigating the following
parameters: selectivity, linearity, identification and quantitation
limits (LOD and LOQ), precision, accuracy and matrix
effect. The linear calibration model was checked by analyzing
(three replicates) blank samples spiked with U-47700 standard
solution at final concentrations of 0, 10, 25, 50, 100, and
250 ng/mL. Whenever the effective drug concentration exceeded
the calibration range, the extract was diluted in order to fit
the quantitation interval considered in the curve. Ten different
blank samples were prepared as previously described to test the
selectivity of the whole analytical procedure. The occurrence of
possible interferences from endogenous substances was checked
by monitoring the signal to noise ratio (S/N) for the U-47700
SRM transitions at the expected retention time. LOD values were
estimated as the analyte concentration whose response provided
a S/N value equal to 3, as determined from the least abundant
transition. The S/N value at the lowest concentration was used
to extrapolate the theoretical LOD. This calculated LOD was
then experimentally confirmed by analyzing spiked samples at
LOD concentration of U-47700. LOQ was calculated as three
times the LOD. Within-batch precision (expressed as percent
variation coefficient, CV%) and accuracy (expressed as bias %),
were assessed by extracting and analyzing a series of ten blood
samples fortified at 50 ng/mL. Matrix effect was evaluated by
comparing the signal obtained when the analyte was added to
the matrix extract with the response obtained from a methanolic
solution containing the analyte at the same concentration. The
percent difference represented either matrix suppression (value
below 100%) or matrix enhancement (value above 100%).
RESULTS AND DISCUSSION
The calibration plot showed good linearity in the range
0–250 ng/mL, with a determination coefficient of 0.998. The SRM
chromatograms from ten negative samples of blood showed no
interfering signals (i.e., S/N ratio lower than 3) at the retention
time of U-47700, indicating that the method is selective and free
from matrix interferences. The calculated LOD was 0.6 ng/mL
and the LOQwas fixed at 2 ng/mL. The results show a satisfactory
within-batch precision (CV%: 3.1) and accuracy (bias%: 11.7)
at 50 ng/mL. No significant matrix effect was observed (matrix
effect 4.0%).
The presence of U-47700 was confirmed in all specimens.
Figure 1 depicts the SRM profiles obtained from the blood,
urine and pubic hair samples for the detection of the target
analyte. U-47700 was quantified at a concentration of 380 ng/mL
in blood while higher amount of the drug was detected in
urine (10,300 ng/mL, creatinine 156 mg/dL). No other drugs nor
ethanol were detected in the body fluids. Pubic hair analysis
revealed past exposure to U-47700 (5.7 ng/mg). Moreover, pubic
hair turned out negative for the presence of traditional drugs
of abuse, synthetic cathinones and synthetic cannabinoids. U-
47700 was also identified as the main component of the white
powder (purity 99%) and of the liquid content of the nasal spray
bottles (0.1 mg/ml). The presence of the substance in the nasal
spray bottles together with the absence of injection signs on the
body indicated that one of the consumptionways was presumably
intranasal.
Presently, several intoxication cases related to the
consumption of U-47700 alone, or in combination with
other drugs, were recently reported (Coopman et al., 2016; Elliott
et al., 2016; Mohr et al., 2016; Armenian et al., 2017; Dziadosz
et al., 2017; Jones et al., 2017; McIntyre et al., 2017; Papsun
et al., 2017; Vo et al., 2017; Koch et al., 2018), but reference toxic
and lethal concentrations in body fluids and organs are not yet
available for U-47700. Intoxication cases involving U-47700 are
summarized in Table 1.
A brief description of the most significant cases is presented as
follows.
A 41-year-old woman presented to the emergency department
(ED) for altered mental status, pinpoint pupils and respiratory
depression which reversed after 0.4mg naloxone administration
intravenously. The U-47700 concentration in the serum,
recorded at the arrival at the ED, was 7.6 ng/mL (Armenian et al.,
2017). Other relevant findings included fentanyl (15.2 ng/mL),
hydrocodone (107.6 ng/mL), sertraline (15.7 ng/mL) and
gabapentin (350.9 ng/mL).
A 26-year-old womanwas found cyanotic andwith respiratory
depression after a nasal insufflation and injection of a product
called “U4” (Jones et al., 2017). Toxicological analysis revealed
the presence of U-47700 in serum and urine samples at
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FIGURE 1 | Comparison between the UHPLC-MS/MS extracted ion chromatogram resulting from the detection of U-47700 in the victim’s blood, urine and pubic hair
(left) and a blank blood, urine and hair samples (right).
concentrations of 228 and 393 ng/mL, respectively. Also in this
case the patient became more responsive after an intravenous
naloxone administration.
Another case involving a 29-year-old man found
unresponsive after the intravenous injection of U-47700
was described (Vo et al., 2017). The patient regained
consciousness spontaneously before the transportation
at the ED. Serum sample was positive for U-47700 and
phenazepam at a concentrations of 240 ng/mL and 1.4 mg/L,
respectively.
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TABLE 1 | U-47700 blood concentration in intoxication cases.
Intoxication
outcome
Country Year Blood (ng/mL) Specimena (site of
sampling)
Other relevant findings (ng/mL) References
Fatal Italy 2017 380 cb (heart) None Presented case
Non-fatal USA 2016 7.6 serum Fentanyl (15.2), Hydrocodone (107.6 ),
Sertraline (15.7 ), Gabapentin (350.9)
Armenian et al., 2017
Non-fatal USA 2016 228 serum None Jones et al., 2017
Non-fatal USA 2016 240 serum Phenazepam (1,400) Vo et al., 2017
Fatal Germany 2017 370 serum Flubromazepam (830) Koch et al., 2018
Fatal USA 2016 190
340
pb (femoral) cb
(heart)
Alprazolam (120), Doxylamine (300),
Diphenhydramine (140), Carboxy-THC (2.4)
McIntyre et al., 2017
Fatal UK 2016 1,460 pb (femoral) Quetiapine, Amphetamine Elliott et al., 2016
Fatal Belgium 2016 13.8 pb (subclavian) Fentanyl (10.9), Sertraline (180) Coopman et al., 2016
Fatal Germany 2017 525
1,347
pb (femoral) cb
(heart)
Diphenidine (1.7), Methoxiphenidine (26) Dziadosz et al., 2017
Fatal Germany 2017 819
1,043
pb (femoral) cb
(heart)
Diphenhydramine (45), Methylphenidate (2.5) Dziadosz et al., 2017
Fatal USA 2017 189 pb (femoral) Oxycodone (67) Papsun et al., 2017
Fatal USA 2017 547 pb (femoral) Etizolam Papsun et al., 2017
Fatal USA 2015–16 382 pb (n/a) Amphetamine (12) Mohr et al., 2016
Fatal USA 2015–16 217 pb (femoral) Mephedrone (22), Etizolam Mohr et al., 2016
Fatal USA 2015–16 334 pb (n/a) None Mohr et al., 2016
Fatal USA 2015–16 252 pb (n/a) Citalopram (43) Mohr et al., 2016
Fatal USA 2015–16 453 blood None Mohr et al., 2016
Fatal USA 2015–16 242 pb (n/a) Carboxy-THC (5.3) Mohr et al., 2016
Fatal USA 2015–16 103 n/a Diphenhydramine (694) Mohr et al., 2016
Fatal USA 2015–16 299 cb (aorta) Alprazolam (47), Lorazepam (11),
3-methoxyphencyclidine (180), Tramadol
(<250)
Mohr et al., 2016
Fatal USA 2015–16 487 cb (aorta) Etizolam (86), diphenhydramine (250),
chlorpheniramine (<250)
Mohr et al., 2016
Fatal USA 2015–16 311 cb (aorta) Oxycodone (11), Venlafaxine (2600),
o-desmethylvenlafaxine (380)
Mohr et al., 2016
Fatal USA 2015–16 59 cb (aorta) None Mohr et al., 2016
Fatal USA 2015–16 135 cb (aorta) Furanylfentanyl (26), Ethanol Mohr et al., 2016
Fatal USA 2015–16 167 cb (aorta) Furanylfentanyl (56), Morphine (48),
6-monoacetylmorphine
Mohr et al., 2016
Fatal USA 2015–16 490 cb (aorta) Furanylfentanyl (76) Mohr et al., 2016
Fatal USA 2015–16 105 cb (aorta) Furanylfentanyl (2.5) Mohr et al., 2016
Fatal USA 2015–16 17 pb (n/a) Butyrylfentanyl (26), Ethanol (0.03 g/dL) Mohr et al., 2016
apb, peripheral blood; c, central blood; s, serum; n/a, data not available.
A fatal intoxication related to the effect of the U-47700
in combination with the benzodiazepine flubromazepam was
recently reported (Koch et al., 2018). A 24 year-old man
suffered apnoea and after reanimation and hospital admission,
hypoxic cerebral damage and severe brain oedema were
stated. Six days after admission mechanical ventilation was
discontinued and the patient died. Serum sample collected at
the admission to the hospital was positive for U-47700 and
flubromazepam at a concentrations of 370 ng/mL and 830 mg/L,
respectively.
McIntyre et al. described a fatal intoxication case related to the
intake of powder containingU-47700, likely by nasal insufflations
(McIntyre et al., 2017). The drug was detected in several post-
mortem samples including peripheral blood (190 ng/mL) and
the central blood (340 ng/mL). Further presence of U-47700 was
determined in liver (1,700 ng/g), vitreous humor (170 ng/mL),
urine (360 ng/mL) and gastric content at trace amount
(<1mg).
Another fatal intoxication case associated with the
consumption of U-47700 was reported by Elliott et al. (2016).
The U-47700 concentration in the femoral blood of a man found
dead at home was 1,460 ng/mL.
The presence of U-47700 was found in blood and urine
in a case of 30-year old man found dead in his home after
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inhaling fumes of a powder burned on aluminum foil (Coopman
et al., 2016). U-47700 was quantified in post-mortem blood and
urine at concentrations of 13.8 and 71 ng/mL, respectively. Toxic
levels of fentanyl were also measured in the subclavian blood
(10.9 ng/mL). The dead was ascribable to the concomitant intake
of U-47700 and fentanyl.
In two cases in which the cause of death was explained
by the consumption of U-47700, the concentration of the
drug in femoral blood was 525 ng/mL (case 1) and 819 ng/mL
(case 2) (Dziadosz et al., 2017). The presence of U-47700 was
quantitatively confirmed in additional specimens including heart
blood (1,347 ng/mL in case 1 and 1,043 ng/mL in case 2), urine
(1,393 and 1,848 ng/mL), kidney (2.7 and 1.4 ng/mg), liver (4.3
and 3.1 ng/mg), lung (3.2 and 2.4 ng/mg), and brain (0.97 and 1.1
ng/mg).
Other two fatal cases involving U-47700 were reported
by Papsun et al. (2017). The concentrations of U-47700
in femoral blood were 189 and 547 ng/mL respectively.
In the first case oxycodone was also found in blood at
significant levels (67 ng/mL) and the death was ascribed to
an acute oxycodone and U-47700 overdose. In the second
case, the presence etizolam was found together with U-
47700. The death was attributed to a U-47700 and etizolam
intoxication.
The application of a LC-MS/MS method for the simultaneous
analysis of U-47700, U-50488 and furanyl-fentanyl in blood
specimens related to 20 postmortem cases, initially attributed
to heroin or other opioid-related drug overdoses, was recently
described (Mohr et al., 2016). The presence of U-47700 was
confirmed in 16 of 20 cases. The U-47700 was the only
opioid detected in 9 cases, while in two cases two prescription
opioids were detected (tramadol and oxycodone) and in
the remaining 5 cases the drug was found in combination
with furanylfentanyl (3 cases), morphine and furanylfentanyl
(1 case) and fentanyl (1 case). For U-47700, the mean
concentration (N = 16) was 253 ng/mL, within a range of
17–490 ng/mL.
It is challenging to speculate about which U-47700 levels
in blood might be fatal. The available literature deals with
cases in which the molecule was detected by means of different
analytical techniques in subjects with different characteristics.
Furthermore, in most cases U-47700 was not used alone,
thus other compounds might have been a contributing factor
in the death. In particular, several authors reported the
finding of other opioids, including fentanyl and analogs,
which likely intensified the central nervous system and
respiratory depression. Currently, the sporadic records in
which U-47700 was the only detected toxic agent suggest
to be cautious before any definitive lethal concentration is
presented.
In the present case, the heart blood concentration of U-
47700 was comparable with those reported in some other fatal
cases previously described, where no other drugs were found to
play a role in the intoxication (Mohr et al., 2016). As a matter
of fact, the U-47700 blood concentration was also comparable
with those recorded in some cases of non-fatal intoxication
(Jones et al., 2017; Vo et al., 2017), although in the latter cases
these values were obtained from peripheral blood. In one of
these cases, there was a prompt resuscitation of the patient
at the ED using naloxone (Jones et al., 2017), while in the
second case the patient regained consciousness spontaneously
(Vo et al., 2017). In the present case, the comparison of the U-
47700 concentration in blood and urine (the latter showing a
much higher value, also in light of the high density) suggests
the occurrence of extensive drug excretion and possibly a
long agony before death. Moreover, the presence of U-47700
in the pubic hair sample indicates that the decedent had
previously been exposed to the same drug on more than one
occasion.
CONCLUDING REMARKS
In the fatal case reported here, the intake of U-47700 was
proved and suggests that its depressant effect on the central
nervous system was likely to account for the consumer’s death.
U-47700 was present in body fluids at a concentration compatible
with acute intoxication conditions, possibly leading to death.
To the best of our knowledge, this is the first reported case
of fatal intoxication involving U-47700 that occurred on the
Italian territory. Intoxication cases involving NPS, including
U-47700, continue to pose challenges for toxicologists. Deaths
and intoxication cases consistent with opioid consumption,
but negative to the traditional drug screenings, should be
subjected to further testing for the detection of fentanyl
analogs and novel opioid-like compounds. Moreover, in all
fatalities involving opiates and opioids, where the toxic effect
is related with acquired tolerance through frequent use, the
interpretation of post-mortem drug concentration may be
challenging. The absence of reference concentrations in post-
mortem matrices together with the contribution of other
drugs to the intoxication makes the interpretation even more
problematic.
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